#United States #New York #Faruqi & Faruqi #Josh Wilson #Zenas BioPharma

Investor Alert: Investigation into Zenas BioPharma

In a recent announcement, Faruqi & Faruqi, LLP, a reputable national securities law firm, has initiated a formal investigation concerning potential claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO). This investigation is focused on shareholders who sustained losses surpassing $75,000 due to alleged corporate misrepresentations.

Background of the Investigation

The firm's Securities Litigation Partner, James (Josh) Wilson, encourages affected investors to reach out directly to discuss their legal options. The focus is primarily on individuals who engaged in the acquisition of Zenas shares, especially during its initial public offering (IPO) around September 13, 2024. This investigation comes at a crucial time, as investors are reminded of a fast-approaching June 16, 2025 deadline to file for lead plaintiff status in a federal securities class action lawsuit against the company.

Faruqi & Faruqi have asserted that Zenas BioPharma may have violated federal securities laws by issuing misleading statements regarding the company’s financial stability. Notably, it has been alleged that Zenas overstated its ability to sustain operational funding through existing cash reserves and proceeds from its IPO. The firm suggests that such misleading statements led to substantial investor damages when the actual financial situation was revealed.

What Investors Need to Know

Investors who believe they qualify within the parameters of the class action are encouraged to consider their options. Faruqi & Faruqi highlights that any member of the prospective class can aim to become the lead plaintiff—the individual representing the interests of the entire class—by working with their counsel. Interested parties do retain the option to remain absent from the class while still eligible for any recovery.

The law firm invites anyone with pertinent insights regarding Zenas’ practices, including whistleblowers, former employees, and current or past shareholders, to reach out confidentially. This outreach is crucial to ensure comprehensive investigations and potentially strengthen the case against the company.

Why Acting Soon is Vital

The urgency surrounding this investigation cannot be understated. The date for potential lead plaintiff motions is rapidly approaching, and those interested in participating in the litigation, or simply seeking more information, must act quickly. By being proactive, investors can take the necessary steps to protect their rights and interests.

For additional details regarding the ongoing class action suit against Zenas BioPharma, or to speak with a partner like Josh Wilson, you can visit Faruqi & Faruqi’s website or contact them directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

About Faruqi & Faruqi, LLP

Founded in 1995, Faruqi & Faruqi has established itself as a leading firm in the realm of securities law, successfully recovering hundreds of millions for investors nationwide. With offices spanning from New York to California, their track record speaks to their commitment and expertise within the securities litigation landscape. For media updates, you may follow them on platforms such as LinkedIn, Twitter, or Facebook.

In conclusion, any investors involved with Zenas BioPharma should stay alert to developments surrounding this investigation and consider reaching out as soon as possible to ensure they remain informed and prepared regarding their investment rights.